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Background: The use of autoantibodies for the early detection of breast cancer has generated much interest as
antibodies can be readily assayed in serum when antigen levels are low. Ideally, diagnostic autoantibodies would
be identified in individuals who harbored pre-invasive disease/high risk lesions leading to malignancy. Prospectively
collected human serum samples from these individuals are rare and not often available for biomarker discovery. We
questioned whether transgenic animals could be used to identify cancer-associated autoantibodies present at the
earliest stages of the malignant transformation of breast cancer.
Methods: We collected sera from transgenic mice (TgMMTV-neu) from the time of birth to death by spontaneous
mammary tumors. Using sera from a time point prior to the development of tumor, i.e. “pre-diagnostic”, we probed
cDNA libraries derived from syngeneic tumors to identify proteins recognized by IgG antibodies. Once antigens
were identified, selected proteins were evaluated via protein arrays, for autoantibody responses using plasma from
women obtained prior to the development of breast cancer and matched controls. The ability of the antigens to
discriminate cases from controls was assessed using receiver-operating-characteristic curve analyses and estimates
of the area under the curve.
Results: We identified 6 autoantibodies that were present in mice prior to the development of mammary cancer:
Pdhx, Otud6b, Stk39, Zpf238, Lgals8, and Vps35. In rodent validation cohorts, detecting both IgM and IgG antibody
responses against a subset of the identified proteins could discriminate pre-diagnostic sera from non-transgenic
control sera with an AUC of 0.924. IgG and IgM autoantibodies, specific for a subset of the identified antigens, could
discriminate the samples of women who eventually developed breast cancer from case-matched controls who did not
develop disease. The discriminatory potential of the pre-diagnostic autoantibodies was enhanced if plasma samples
were collected greater than 5 months prior to a breast cancer diagnosis (AUC 0.68; CI 0.565-0.787, p = 0.0025).
Conclusion: Genetically engineered mouse models of cancer may provide a facile discovery tool for identifying
autoantibodies useful for human cancer diagnostics.
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A serum test to aid in the diagnosis of cancer has long
been the “holy grail” of early cancer detection. Develop-
ing a blood based diagnostic assay is ideally suited to a
disease such as breast cancer as high risk populations
are defined and current screening tools, specifically mam-
mography, are limited in specific populations, i.e. increased
breast density in young women. Identification of autoanti-
bodies associated with high risk or pre-invasive disease
may facilitate serum-based testing for early detection or
risk stratification. Unlike circulating shed tumor proteins
or nucleic acids, plasma levels of which are dependent on
tumor size, autoantibodies are elicited in significant con-
centrations even after minimal exposure to the antigen due
to cytokine induced production of antibodies by activated
B cells [1]. Despite the initial promise of autoantibodies as
cancer diagnostic tools, there have been few candidates
that demonstrate significant predictive activity in high risk
women. Progress has been challenged by a focus on single
antibody markers rather than panels, antigen discovery
using samples from individuals already bearing invasive
cancers, and a lack of understanding of antibody kinetics
developing in pre-invasive disease.
Genetically engineered mouse models of cancer may
provide a model system for identification of diagnostic
autoantibodies. As mice develop spontaneous breast can-
cers, many in middle age, serum can be collected over time
and samples for discovery can span both disease-free and
disease-bearing states in the same individual. We ques-
tioned whether the TgMMTV-neu model could be used to
identify autoantibody candidates for the early detection of
human breast cancer. Although the TgMMTV-neu ex-
presses the neu proto-oncogene, the genes expressed in
the tumors that arise in these animals is similar to the
genes expressed in human luminal breast cancer [2]. The
mice have a latency period of pre-invasive disease, some-
times of months, before developing mammary cancers
allowing the evolution of an antibody repertoire over time.
We utilized serologic screening of pre-diagnostic sera
against cDNA libraries of syngeneic tumor expressed in
phage to identify antibodies which were present in mice
prior to the diagnosis of cancer that could discriminate
at risk mice from controls. We then explored whether
these autoantibodies had relevance in the early detec-
tion of human breast cancer using plasma samples ob-
tained from the Women’s Health Initiative (WHI) study
and derived from women who would eventually develop
breast cancer as compared to matched controls who
remained free of disease.
Methods
Murine serum samples
TgMMTV-neu mice (strain name, FVB/N-TgN(MM
TVneu)-202Mul) or wild-type FVB mice (JacksonLaboratory, San Diego, CA) were bred under specific
pathogen-free conditions at the University of Washington.
Animal care and use was in accordance with institutional
and national guidelines. The protocol was approved by the
University of Washington Institutional Animal Care and
Use Committee (Protocol number 2878–01). Mice were
enrolled for blood collection and monitoring for spontan-
eous tumor growth between 4–6 weeks of life (Additional
file 1: Figure S1A). Blood samples were collected every
two weeks by retro-orbital bleeding starting at the time of
enrollment until tumor growth dictated euthanasia or
approximately 1 year if no tumors developed. Sera was
separated and stored in 10 μl aliquots at −80°C until use.
Once tumors developed, volume was measured every
other day with Vernier calipers and calculated as the prod-
uct of length × width × height × π/6, or the standard vol-
ume calculation for an ellipsoid shape. A colony of FVB
wild-type parental animals were also bred and enrolled for
blood collection between 4–6 weeks of life following the
identical schema (Additional file 1: Figure S1A) as the
transgenic mice to provide control age- matched sera.
Serum, taken from animals at time-points approximately
1 month prior to the development of palpable tumor, from
20 individual TgMMTV-neu mice were used for the initial
identification of antigens, i.e. pre-diagnostic sera. Pooled
serum from 10 FVB wild-type mice of similar age were
used as controls in initial SEREX screens as described
below (Additional file 1: Figure S1B). Additional single in-
dividual FVB wild-type sera were used to define the kinet-
ics of antibody responses (Additional file 1: Figure S1B,
Figure 1). For two of the time points, the earliest and latest
in each graph, IgG and IgM levels from 20 individual FVB
mice are shown (mean and SEM) (Figure 1).
Verification of the antigens was performed using sera
derived from an additional 21 TgMMTV-neu mice and an
additional 26 FVB age-related wild type mice (Additional
file 1: Figure S1C). For verification, all samples were ana-
lyzed individually. Samples from the transgenic animals
were derived from two time-points in the same individual:
approximately 1 month prior to the development of palp-
able tumors, pre-diagnostic, and the first sample time
point after the development of palpable disease, tumor
bearing (Additional file 1: Figure S1A). Similar aged sam-
ples were analyzed from the parental strain.
Human plasma samples
De-identified pre-diagnostic plasma samples were col-
lected from 188 women that participated in the WHI
Observational Study [3]. These samples consisted of 94
cases (women who eventually developed breast cancer)
and 94 controls. Controls were individually matched 1:1
to cases for several variables including age at enrollment
(±1 year), race, ethnicity, blood draw date, and clinical
center of enrollment. The matching was also performed
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Figure 1 Tumor associated autoantibodies were detected in the sera of TgMMTV-neu mice prior to the development of palpable
disease. Antigen specific IgG (●), IgM (▲) and tumor growth (■) were identified in a single animal and evaluated over time for (A) Pdhx,
(B) Otud6b, (C) Stk39, (D) Lgals8, (E) Vps35 and (F) Znf238. IgG (○) and IgM (Δ) measured over time from control animals (n = 20 (+/−SE for first
and last time points and for an individual control for all intermediate time points). Left Y axis: Tumor volume; right Y axis: antibody concentration
or band density; X axis: mouse age (in weeks). Arrow indicates first palpable tumor. * indicates p < 0.05 from initial value.
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following her blood draw, as the time from blood draw
to breast cancer diagnosis of the case to which she was
matched. Samples were stored at -70°C until use. Samples
from 48 cases and 48 controls were collected greater than
150 days prior to the cases developing breast cancer and
samples from 46 cases and 46 controls were collected
within 150 days of the cases being diagnosed with breast
cancer.
Identification of tumor antigens
Serological screening of cDNA expression libraries
(SEREX) was used to identify tumor associated auto-
antibodies as previously described [4]. Briefly, a cDNA
expression library was constructed from a syngeneic
tumor cell line [4]. Pre-diagnostic serum samples pooled
from 20 individual animals were used for the identificationof autoantibodies. A total of 3 × 106 recombinant clones
per library were screened. A median of 4 (range 0–8)
discrete positive plaques were identified from each group
of 32,000 clones evaluated. The positive plaques were
interrogated with pooled normal FVB serum (Additional
file 1: Figure S1B). Clones that did not react to the FVB
control serum were then purified to moncolonality and
converted to pBluescript phagemid and the nucleotide
sequences of the cDNA inserts were determined using an
ABI Prism automated DNA sequencer. Blast was used to
assess sequence homology. Six unique proteins were
found to elicit autoantibodies in the pre-diagnostic sera of
TgMMTV-neu mice and not the FVB parental serum pool
(Table 1).
Evaluation of autoantibodies in mice. Two methods were
used for the quantitation of murine antibodies; ELISA and
western blot/densitometry. The measurement of serum
Table 1 Pre-diagnostic antigens identified using SEREX

















Vps35 Vacuolar protein sorting 35 Cytoplasm 99%
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lysate ELISA (bacteria expressing the protein of interest) as
previously described with the modification that both IgG
and IgM responses were evaluated (Lu et al. Cancer Re-
search 2006). Experimental serum at a 1:200 dilution and
horseradish peroxidase conjugated goat anti-mouse IgG
(diluted 1:5,000) or IgM (diluted 1:1000; Zymed, San
Francisco, CA) were used. After development, plates were
read at an absorbance of 450 nm. The OD of each serum
dilution was calculated as the OD of the antigen-coated
wells minus the OD of non-antigen encoding lysate-coated
wells. The autoantibody concentration (ng/well) was calcu-
lated from the 4-parameter fitted standard curve on each
plate. All identified antigens were highly homologous be-
tween mouse and man, median 95% (range 80–100).
Human recombinant proteins were available for Otud6b,
Stk39, and Lgals8 (all from Abnova, Walnut CA) and indir-
ect ELISA was performed to measure serum antibodies to
tumor antigens as previously described [5]. Experimental
serum at a 1:200 dilution and goat anti-mouse IgG anti-
body (1:100,000 dilution) or goat anti-mouse IgM antibody
(1:5,000 dilution) (Invitrogen, Grand Island, NY) were
used. Plates were read at 450 nm. The autoantibody con-
centration (ng/well) was calculated from the 4-parameter
fitted standard curve on each plate. Five positive and nega-
tive samples were analyzed by western blot for each anti-
gen with each assay demonstrating a sensitivity and
specificity greater than 75%.
The assessment of Vps35 and Znf238 autoantibodies
was performed by Western blot and densitometry as the re-
combinant proteins gave insufficient signal in ELISA. 3
pmole recombinant protein of Vps35 or Znf238 (Abnova)
were loaded on SDS-PAGE gel and transferred onto
nitrocellulose membranes (Amersham Pharmacia Biotech,
Piscataway, NJ). After blocking with 5% nonfat milk, mem-
branes were incubated with mouse sera (diluted 1:100)
overnight. Then the membranes were washed with TBS/
0.05% Tween 20 and incubated with peroxidase-labeled
goat anti-mouse IgG (1:1,000 dilution) or IgM (1:500 dilu-
tion) secondary antibody (Invitrogen). After washing, bandswere visualized using a peroxidase-linked enhanced chemi-
luminescence detection system (Amersham Pharmacia Bio-
tech) and the optical density of the specific band was
quantified with ImageJ software.
Evaluation of antigen expression in human DCIS. To
evaluate whether these identified antigens had the poten-
tial for being expressed in human pre-invasive lesions, a
GEO dataset, GSE26304, was analyzed for expression of
the genes encoding the identified pre-diagnostic antigens
[6]. This published gene expression data was derived from
31 ductal carcinoma in situ (DCIS) and 36 invasive ductal
carcinomas (IDC). Six normal breast tissue samples were
included as controls. Data for the pre-diagnostic antigens
are expressed as normalized to beta actin. The mean value
and 2 standard deviations of the expression of a particular
antigen in normal breast tissue was calculated to deter-
mine the incidence of DCIS or IDC samples having higher
expression of the candidate antigens compared to normal
breast tissue.
Evaluation of pre-diagnostic autoantibodies in women
without cancer
Due to the low volume of sample available for analysis,
serum autoantibodies to only 3 antigens, Otud6B, Stk39,
and Pdhx, were assessed using customized protein mi-
croarrays as previously described [7]. We chose these
proteins as, in mice, antibodies to these 3 antigens were
significantly elevated at multiple time points prior to the
development of clinically palpable cancer (Figure 1). In
brief, recombinant proteins were arrayed in duplicate onto
nitrocellulose-coated slides using a contact printer. Plasma
samples (diluted 1:150) were hybridized with the protein
microarray for 3 hours at 4°C. Slides were then incubated
with Cy5-labeled anti-human IgG for 1 hour at 4°C,
followed by incubation with Cy3-labeled anti-human IgM
for 1 hour at 4°C. Local background-subtracted median
spot intensities for downstream statistical analysis of both
IgG and IgM were generated using GenePix software.
Statistical analysis
For all analysis, significance was assessed using a two-
tailed T test or ANOVA with p < 0.05 being considered
significant. Differences in the incidence of an antibody
response between transgenic mice and controls were
evaluated using a x2 test. The sensitivity and specificity
of a single or combination of antibodies in mice was
evaluated using receiver-operating-characteristic (ROC)
curve analyses, leading to estimates of the area under
the curve (AUC), with 95% confidence intervals. Statistical
analysis was carried out in SPSS software, version 15.0.
For protein arrays, ROC analysis of marker combinations
was performed using a linear regression model based on
maximum likelihood estimation. AUC and 95% confi-
dence intervals were calculated using R v2.13.1.
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Tumor associated autoantibodies were detected in the
sera of TgMMTV-neu mice prior to the development of
palpable disease
Pre-diagnostic autoantibodies directed against six tumor
associated antigens were identified in individual TgMM
TV-neu mice at significantly higher levels compared to
wild-type controls (p < 0.01 for each antigen) (Table 1,
Figure 1). The antigens are all intracellular proteins of
diverse functions and are involved in glycolysis, signaling,
and cell adhesion pathways. Half of the antigens (Pdhx,
Lgals8, and Otud6) have also been associated with in-
flammation and/or autoimmunity. All are highly hom-
ologous to a corresponding human protein (Table 1).
Tumor growth and antibody kinetics are shown for the
individual animals in which the specific antibody was
detected (Figure 1). In all individuals, antigen specific
IgG antibodies significantly increased over time (p < 0.05
compared to baseline) prior to tumor detection (Figure 1,
A-F). Autoantibodies specific for Lgals8 and Znf238 were
discovered in mice that did not develop tumor during the
time course of the study (Figure 1, D, E). IgM antibodies
were also detected prior to palpable breast tumors in most
animals, in some cases at much higher levels than IgG
(Figure 1B, D-F). In general, levels of IgM antibodies
decreased over time, while IgG antibodies either in-
creased or persisted at measurable levels after tumor
development.
Both IgG and IgM responses are needed to discriminate
serum derived from mice destined to develop tumor as
compared to controls
We further evaluated the prevalence of the pre-diagnostic
autoantibodies in serum samples taken from an additional
21 transgenic animals not used for the autoantibody dis-
covery. The incidence of autoantibodies to an individual
antigen in mice, both pre and post tumor development, is
shown in Figure 2. The incidence of response to the anti-
gens, prior to the development of palpable tumor, ranged
from 5% (Pdhx) to 30% of mice for Vps35 for IgG. For
IgM, prior to tumor detection, incidence of autoanti-
body responses ranged from 0% (Pdhx) to 30% (Otud6b)
(Figure 2A). In tumor bearing mice, IgG autoantibody
incidence ranged from 5% (Pdhx, Stk39) to 50% (Lgals8).
IgM responses were found in 0% (Pdhx, Lgals8) to 20%
(Stk39) of tumor bearing mice (Figure 2B). The incidence
of IgG or IgM autoantibodies to any of the identified
antigens was less than 10% of the 20 control mice, with
the exception of Znf238 (22% for IgG). While IgG anti-
bodies to any of the antigens could be detected in 68% of
tumor bearing samples, IgM responses to the same pro-
teins were present in only 25% (p < 0.05) (Figure 2D). In
pre-diagnostic sera, IgM antibodies could be detected in
over half the mice at levels similar to the antigen specificIgG antibodies (Figure 2C). For a panel of all 4 markers,
56% of pre-diagnostic sera contained IgG antibodies to
any of the antigens and 50% contained IgM. No individual
responded to more than 4 of the antigens.
To assess the potential utility of the autoantibodies in
discriminating those animals that would develop mam-
mary tumors (pre-diagnostic and tumor bearing sam-
ples) from FVB controls, ROC were generated and AUC
calculated (Table 2). The performance of IgG antibodies
was equivalent in discriminating both case sample sets
from controls with a panel of 3 markers demonstrating
superior performance. A combination of Otud6b, Stk39
and Lgals8 gave an AUC of 0.868 (95% CI 0.744-0.968,
p < 0.001) for pre-diagnostic sera and 0.871 for sera de-
rived from tumor bearing mice (95% CI 0.744-0.976, p <
0.001) with a sensitivity of 0.75 and specificity of 0.8.
The performance of the 3 antigen panel for IgM was
superior in the pre-diagnostic sera with an AUC of 0.841
(95% CI 0.7-0.966, p < 0.001) with a sensitivity of 0.7 and
specificity of 0.9 as compared to tumor bearing sera, at
0.676 (95% CI 0.48-0.84, p = 0.141). A combination of
IgG and IgM was most effective in modeling early detec-
tion with an AUC of 0.924 (95% CI 0.81-1.0, p < 0.001)
with a sensitivity of 0.85 and specificity of 0.9 discriminat-
ing pre-diagnostic sera from FVB controls. Once animals
had evidence of palpable tumor, the AUC decreased to
0.676 (95% CI 0.48-0.84, p = 0.141) (Table 2). All AUC for
the various combinations are shown in Additional file 1:
Table S1.
Pre-diagnostic tumor antigens identified in mice may be
useful for the early detection of human breast cancer
To explore the relevance of these antigens to human
pre-invasive disease, we evaluated gene expression in an
existing data set of normal breast, DCIS, and IDC. 10%
of DCIS expressed Pdhx (Figure 3A), Lgals8 (Figure 3D)
and Znf238 (Figure 3F) at levels greater than 2 standard
deviations above normal breast tissues. Lgals8 (Figure 3D)
was also expressed above normal levels in 17% of IDC.
Stk39 (Figure 3C) gene expression was upregulated in 50%
of both DCIS and IDC compared to normal breast tissue
(p < 0.05). Otud6b and Vps35 expression was similar across
all samples (Figure 3B, E).
As human homologues of the murine pre-diagnostic
antigens exist and the proteins appear to be expressed in
human pre-invasive breast lesions, we explored the po-
tential utility of three of the antigens, Pdhx, Otud6B,
and Stk39 in discriminating women who would eventu-
ally develop cancer from controls (Table 3). Limited vol-
umes of samples available limited our exploration to 3 of
the 6 identified proteins. Otud6B and Stk39 were chosen
as part of the panel of antigens that demonstrated super-
ior performance in the mice. Pdhx was added as this
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Figure 2 IgM antibodies to pre-diagnostic antigens are more commonly identified in sera from mice prior to the development of
palpable breast cancer. Incidence of IgG (black bar) and IgM (white bar) for antigen Pdhx, Otud6b, Stk39, Lgals8, Znf238 and Vps35 in sera
obtained (A) pre-diagnosis or when (B) tumor bearing. Incidence of IgG (black bar) and IgM (white bar) antibody detection for a panel with any
1 antigen, 2 antigens, 3 antigens and 4 antigens in sera obtained (C) pre-diagnosis or when (D) tumor bearing.
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bodies were significantly elevated at the earliest time
points tested in the mice (Figure 1A). An evaluation of
the population as a whole revealed a range of AUC for
IgG and IgM responses from 0.52-0.56 for each individ-
ual antigen. A panel of all three gave an AUC of 0.59
(95% CI 0.512-0.675, p = 0.026) for IgG, 0.56 (95% CI
0.481-0.645, p = 0.135) for IgM and the combination of
IgG and IgM, 0.59 (95% CI 0.511-0.674, p = 0.028).
Kinetic studies in mice (Figure 1) demonstrated signifi-
cant fluctuation in IgM antibody levels in time periods
distant to tumor detection. We, therefore, evaluated the
performance of the antibody panel on the pre-diagnostic
human samples separated by the case median time-Table 2 AUC of IgG and IgM antibodies against pre-diagnosti
Antigens IgG







Otud6b + Stk39 + Lgals8 0.868 0.871from-diagnosis (150 days) (Table 4). A linear regression
analysis of IgG responses demonstrated more discrimin-
ation between case and control for samples collected
greater than 150 days prior to diagnosis, AUC = 0.62
(95% CI 0.506-0.735, p = 0.043), than those collected closer
to diagnosis, AUC = 0.59 (95% CI 0.476-0.707, p = 0.123).
A combination of the 3 antigens for IgM responses were
equivalent for samples collected both further from diagno-
sis, AUC = 0.61 (95% CI 0.493-0.727, p = 0.068), and those
collected closer to diagnosis, AUC = 0.61 (95% CI 0.495-
0.722, p = 0.064). A combination of both Ig isotypes in-
creased the AUC of both groups, but was superior for the
samples collected greater than 150 days prior to diagnosis,
AUC 0.68 (CI 0.565-0.787, p = 0.003). The sensitivity andc antigens
IgM IgG + IgM
iagnostic Tumor bearing Pre-diagnostic Tumor bearing
0.500 0.500 0.507 0.507
0.782 0.574 0.818 0.658
0.582 0.547 0.704 0.591
0.732 0.574 0.737 0.593
0.503 0.500 0.508 0.500
0.661 0.541 0.648 0.534































































Figure 3 Pre-diagnostic autoantibodies target proteins that may be expressed in pre-invasive breast lesions. Gene expression relative to
beta actin for Pdhx (A), Otud6b (B), Stk39 (C), Lgals8 (D), Vps35 (E) and Znf238 (F) in normal breast (n = 6), DCIS (n = 31) and IDC (n = 36).
Dashed line; mean + 2SD of normal breast tissue for each antigen. * indicates p < 0.05.
Mao et al. Journal of Translational Medicine 2014, 12:121 Page 7 of 10
http://www.translational-medicine.com/content/12/1/121specificity of the IgG+ IgM panel in discriminating women
greater than 150 days from their breast cancer diagnosis
from control is 67% and 65% respectively. We had previ-
ously screened the WHI pre-diagnostic sera for antibodies
to HER2, p53 and cyclin B1 using the same approach [8].
Combination of IgG and IgM to all 6 antigens further in-
creased the AUC to 0.75 in samples collected greater than
150 days from diagnosis.
Discussion
We questioned whether the use of genetically engineered
mouse models of mammary cancer could serve as a tool
for developing autoantibody panels useful for the earlyTable 3 WHI sample characteristics
Less than 150 D
Cases
Number 48





Days prior to diagnosis 82.4 (12–148)detection of human breast cancer and/or improved strati-
fication of risk. The identification of cancer predicting
autoantibodies, using individuals bearing early stage inva-
sive breast cancers, may not encompass antigens associ-
ated with the earliest high risk lesions, thus may limit the
utility of any identified panel for screening a general popu-
lation. Transgenic mouse models of mammary cancer
have been shown to have significant genetic similarities to
human breast cancer [2]. In addition, the serum autoanti-
body repertoire induced in mouse and man by breast can-
cer is also similar [4]. Using SEREX, and screening tumor
cDNA libraries expressed in phage with sera from cancer
bearing mice, a tumor associated autoantibody repertoireays Greater than 150 Days
Controls Cases Controls
48 46 46





- 209.2 (151 – 264) -
Table 4 AUC of IgG and IgM antibodies against
pre-diagnostic antigens based on time to diagnosis
Antigens Greater than 150 days Less than 150 days
IgG IgM IgG + IgM IgG IgM IgG + IgM
Phdx 0.62 0.56 0.62 0.52 0.56 0.57
Otud6b 0.53 0.57 0.58 0.58 0.48 0.58
Stk39 0.51 0.50 0.49 0.52 0.60 0.60
All 3 0.62 0.61 0.68 0.59 0.61 0.63
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identified antigens were reported as human tumor anti-
gens in a variety of cancers. Data presented here demon-
strate that a pre-diagnostic autoantibody repertoire can be
identified in mice prior to the development of spontan-
eous tumors and these antibodies may be useful for the
detection of human breast cancer. Further, our work
shows that detection with a combination of both IgG and
IgM antibodies for a specific antigen may improve the
ability to identify patients harboring the disease at time
points more distant from diagnosis than is achievable by
the use of IgG autoantibodies alone.
There have been several studies that have explored the
use of autoantibody panels in the early detection of breast
cancer. All have assessed sera from disease bearing indi-
viduals and several have focused on well-known tumor
associated antibodies such as HER2, p53, NY-ESO, and
MUC1 for example [8,9]. In an evaluation of 94 patients
with breast cancer and 40 patients with DCIS, the per-
centage of patients with detectable autoantibodies specific
for a panel of 7 known tumor associated antigens, ranged
from 55-73% in patients with invasive tumors but only
20-62% in women with DCIS (based on responses in
volunteer controls) [9]. A variety of investigations have
evaluated array-based approaches in identifying auto-
antibodies that are associated with discriminating DCIS
from invasive breast cancer [10-12]. Almost all the auto-
antibodies identified were intracellular proteins. The
panels could discern DCIS from invasive cancers with
AUCs of approximately 0.7-0.8 although none have been
explored in high risk women. All the identified panels
contained proteins that could be implicated in cancer biol-
ogy and pathogenesis [11].
The autoantibodies we found in the pre-diagnostic
sera of TgMMTV-neu mice, animals that had not yet
developed invasive cancers, were also directed against
intracellular proteins. Half of the antigens identified are
also associated with inflammation and immunity. Pdhx,
a glycolysis protein, is an antigenic component of anti-
mitochondrial autoantibodies. The majority of patients
with primary billiary cirrhosis have autoantibodies di-
rected against Pdhx [13]. Lgals8 is a cytosolic lectin which
has recently been shown to bind to damaged host glycans
and stimulate autophagy [14]. Antibodies to Lgals8 havebeen identified in a variety of autoimmune diseases in-
cluding systemic lupus erythematosis and rheumatoid
arthritis and may play a role in regulating autoimmune in-
flammation [15,16]. Otud6b is a protease that cleaves ubi-
quitin linkages and its expression has recently been shown
to be involved in the regulation of B cell proliferation after
cytokine stimulation [17]. The remaining antigens have no
link to inflammation. Stk39 functions in the cellular stress
pathway and activates p38 MAP kinase. Stk39 is involved
in cation-chloride transport and polymorphisms in this
gene are associated with the development of hypertension
[18]. Zfp238, a transcription repressor protein has been
shown to be necessary for neuronal survival and develop-
ment [19]. Vps35 is part of a larger complex involved in
retrograde transport of proteins from endosomes to Golgi.
Mutations in Vps35 have been associated with the devel-
opment of Parkinson’s disease [20]. None of the proteins
has been shown to play a major role in breast cancer
initiation or progression. Inflammation has long been
associated with cancer initiation due to the proliferative
environment induced by innate immune cells and B
cells [21]. The presence of inflammation associated and
autoimmune related antibodies in our panel may be re-
flective of alterations occurring at the earliest stages of
the malignant transformation. However, as these auto-
antibodies may also be elevated in women with chronic
inflammatory and autoimmune disease, and their po-
tential clinical utility for screening might be limited in
this population.
Genes encoding homologues of murine pre-diagnostic
antigens are found in human breast, DCIS, and invasive
cancers. Our studies demonstrate that women who eventu-
ally develop breast cancer have evidence of autoantibodies
targeting these pre-diagnostic antigens prior to their first
diagnosis of disease. A limited panel of only 3 of the auto-
antibodies could discern women destined to develop breast
cancer from matched controls that did not develop disease
with an AUC approaching 0.7. Key to this finding was the
use of both IgG and IgM antibodies for detection and
assessing sera at a time point more distant from diagnosis.
IgM antibodies are the first antibodies secreted by B cells
in response to an antigen. B cell proliferation and IgM pro-
duction are induced simultaneously via cytokine secretion
by a number of different immune cells [22]. As T cells
become involved in antigen recognition, immunoglobulin
class switching occurs with IgG responses becoming pre-
dominant and persistent and IgM antibodies wane. Indeed,
several lines of evidence suggest that the presence of IgM
antibodies will increase the secretion of IgG antibodies to
greater levels than those achieved if IgM antibodies are not
present [22]. The kinetics of both the IgG and IgM
antibody response in the TgMMTV-neu mice (Figure 1)
demonstrate that antigen specific IgM levels may be quite
elevated in the time period distant from diagnosis, but
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what is observed in viral infections. The ability to detect
both IgG and IgM autoantibodies appears to provide
broader population coverage in the pre-diagnostic set-
ting in the mice and our data in women would indicate
the same. A yearly screening strategy, for example, may
capture a time point where both IgM and IgG anti-
bodies are elevated potentially increasing the sensitivity
of serologic screening with autoantigens.
The ideal method to develop an autoantibody panel
for the early detection of breast cancer would be to dis-
cover autoantigens in women who have not yet devel-
oped invasive cancer but are destined to do so. The use
of genetically engineered mice that develop spontaneous
tumors, allows investigators to model studies such as
WHI and collect samples from individuals who have not
yet developed cancer but will do so in a defined period
of time. Genetic and protein based analyses suggest that
there is enough similarity between cancers arising in
mice and people that discovery methods in mice might
be applicable to human cancer diagnostics.
Conclusions
Data presented in this report suggest that, at least for
breast cancer, mining the pre-diagnostic autoantibody rep-
ertoire of transgenic mice yields viable biomarker candi-
dates for the early detection of the disease.
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